$-0.08
(Market cap
$2,730 Mln
Recently Viewed
Clear AllMarket cap
$2,730 Mln
Revenue (TTM)
$190 Mln
P/E Ratio
135.3
P/B Ratio
6.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
87.2
Debt to Equity
0
Book Value
$8.7
EPS
$0.4
Face value
--
Shares outstanding
51,718,149
CFO
$-166.00 Mln
EBITDA
$-209.73 Mln
Net Profit
$-211.01 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Soleno Therapeutics (SLNO)
| 13.9 | 66.3 | 24.5 | -27.0 | 137.3 | 24.2 | -5.7 |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Soleno Therapeutics (SLNO)
| 3.0 | 11.6 | 1,932.8 | -67.8 | -78.8 | -34.4 | 71.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Soleno Therapeutics (SLNO)
|
52.8 | 2,729.7 | 190.4 | 20.9 | 13.8 | 6 | 135.3 | 6.1 |
| 74.9 | 9,733.6 | 1,091.0 | 202.3 | 31.6 | 31.3 | 43.4 | 17.1 | |
| 224.0 | 15,009.4 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 65.4 | 8,216.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 45.1 | 11,658.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 89.4 | 11,852.6 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 520.8 | 12,204.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.3 | |
| 415.6 | 14,867.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.4 | |
| 107.2 | 8,460.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.8 | |
| 339.3 | 9,538.9 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of... Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. Read more
President, CEO, COO & Director
Dr. Anish Bhatnagar M.D.
President, CEO, COO & Director
Dr. Anish Bhatnagar M.D.
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Soleno Therapeutics Inc (SLNO) is $52.76 (NASDAQ) as of 24-Apr-2026 13:35 EDT. Soleno Therapeutics Inc (SLNO) has given a return of 137.26% in the last 3 years.
The P/E ratio of Soleno Therapeutics Inc (SLNO) is 135.33 times as on 17-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
115.25
|
5.35
|
|
2024
|
-10.22
|
7.34
|
|
2023
|
-16.52
|
4.09
|
|
2022
|
-0.66
|
1.53
|
|
2021
|
-0.07
|
0.12
|
The 52-week high and low of Soleno Therapeutics Inc (SLNO) are Rs 90.32 and Rs 29.43 as of 25-Apr-2026.
Soleno Therapeutics Inc (SLNO) has a market capitalisation of $ 2,730 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Soleno Therapeutics Inc (SLNO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.